JP2022513372A5 - - Google Patents
Info
- Publication number
- JP2022513372A5 JP2022513372A5 JP2021547039A JP2021547039A JP2022513372A5 JP 2022513372 A5 JP2022513372 A5 JP 2022513372A5 JP 2021547039 A JP2021547039 A JP 2021547039A JP 2021547039 A JP2021547039 A JP 2021547039A JP 2022513372 A5 JP2022513372 A5 JP 2022513372A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- polypeptide
- acid sequence
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025041321A JP2025085740A (ja) | 2018-10-19 | 2025-03-14 | シアリルルイスaを標的とするキメラ抗原受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748198P | 2018-10-19 | 2018-10-19 | |
| US62/748,198 | 2018-10-19 | ||
| PCT/US2019/057017 WO2020081988A1 (en) | 2018-10-19 | 2019-10-18 | Chimeric antigen receptor targeting sialyl lewis a and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025041321A Division JP2025085740A (ja) | 2018-10-19 | 2025-03-14 | シアリルルイスaを標的とするキメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513372A JP2022513372A (ja) | 2022-02-07 |
| JP2022513372A5 true JP2022513372A5 (cg-RX-API-DMAC7.html) | 2022-10-19 |
| JP7672340B2 JP7672340B2 (ja) | 2025-05-07 |
Family
ID=70283157
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547039A Active JP7672340B2 (ja) | 2018-10-19 | 2019-10-18 | シアリルルイスaを標的とするキメラ抗原受容体およびその使用 |
| JP2025041321A Pending JP2025085740A (ja) | 2018-10-19 | 2025-03-14 | シアリルルイスaを標的とするキメラ抗原受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025041321A Pending JP2025085740A (ja) | 2018-10-19 | 2025-03-14 | シアリルルイスaを標的とするキメラ抗原受容体およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210246221A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3867279A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7672340B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113454115B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020081988A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105764526B (zh) * | 2013-08-26 | 2020-12-15 | 生物技术研发公司 | 编码抗唾液酸化路易斯a抗原的人抗体的核酸 |
| WO2021105989A1 (en) * | 2019-11-26 | 2021-06-03 | Ramot At Tel-Aviv University Ltd. | Chimeric antigen receptor to carbohydrate antigens |
| WO2021105988A1 (en) | 2019-11-26 | 2021-06-03 | Ramot At Tel-Aviv University Ltd. | Antibodies to carbohydrate antigens |
| CN112457416B (zh) * | 2020-12-15 | 2021-08-17 | 吴菲 | 一种靶向bcma的嵌合抗原受体(car)及其应用 |
| CN115876993B (zh) * | 2022-11-17 | 2024-10-15 | 沈阳农业大学 | 基于生物膜干涉技术检测病原生物凝集素与唾液酸乳糖亲和力方法的建立 |
| CN117092046B (zh) * | 2023-08-03 | 2024-03-08 | 首都医科大学附属北京安定医院 | 一种检测精神病患者口腔是否藏匿药物的方法 |
| TW202615101A (zh) * | 2024-06-06 | 2026-04-16 | 德商拜恩技術股份公司 | Ca19-9結合分子 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105764526B (zh) * | 2013-08-26 | 2020-12-15 | 生物技术研发公司 | 编码抗唾液酸化路易斯a抗原的人抗体的核酸 |
| CN122399016A (zh) * | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| WO2015188141A2 (en) * | 2014-06-06 | 2015-12-10 | Memorial Sloan-Kettering Cancer Ceneter | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| DK3227339T3 (da) * | 2014-12-05 | 2022-01-10 | Memorial Sloan Kettering Cancer Center | Kimæriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf |
| CN113698497A (zh) * | 2014-12-05 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| GB201515094D0 (en) * | 2015-08-25 | 2015-10-07 | Univ Nottingham | Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto |
| CA3002097A1 (en) * | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| US20190112380A1 (en) * | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| IL326873A (en) * | 2017-12-29 | 2026-04-01 | Memorial Sloan Kettering Cancer Center | Enhanced chimeric antigen receptors and uses thereof |
-
2019
- 2019-10-18 WO PCT/US2019/057017 patent/WO2020081988A1/en not_active Ceased
- 2019-10-18 JP JP2021547039A patent/JP7672340B2/ja active Active
- 2019-10-18 EP EP19874130.8A patent/EP3867279A4/en not_active Withdrawn
- 2019-10-18 CN CN201980082824.9A patent/CN113454115B/zh active Active
-
2021
- 2021-04-19 US US17/233,994 patent/US20210246221A1/en active Pending
-
2025
- 2025-03-14 JP JP2025041321A patent/JP2025085740A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI800506B (zh) | 免疫結合物 | |
| TWI780140B (zh) | 免疫結合物 | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| KR102411571B1 (ko) | 치료제 | |
| JP2022109915A (ja) | Cd80バリアント免疫調節タンパク質およびその使用 | |
| JP7853916B2 (ja) | 免疫複合体 | |
| JP2017535264A (ja) | 阻害性キメラ抗原受容体 | |
| US11447570B2 (en) | Binding unit targeting fibroblast activation protein α and application thereof | |
| CN114502188B (zh) | 人工免疫监视嵌合抗原受体及其表达细胞 | |
| JP2022527081A5 (cg-RX-API-DMAC7.html) | ||
| JP7812549B2 (ja) | 人工免疫監視キメラ抗原受容体(ai-car)及びそれを発現する細胞 | |
| JP2022548112A5 (cg-RX-API-DMAC7.html) | ||
| CN120548192A (zh) | 免疫缀合物 | |
| JP2024534783A5 (cg-RX-API-DMAC7.html) | ||
| IL324341A (en) | Methods of using il-18 fusion proteins | |
| CN114685659B (zh) | Cd22特异性人源化抗体及利用其的嵌合抗原受体 | |
| JP2021530238A5 (cg-RX-API-DMAC7.html) | ||
| JP2024535740A5 (cg-RX-API-DMAC7.html) | ||
| JP2024532486A5 (cg-RX-API-DMAC7.html) | ||
| JP2022550120A5 (cg-RX-API-DMAC7.html) | ||
| US20250041419A1 (en) | Modified Cytotoxic T Cells and Methods of Use Thereof | |
| HK40123337A (en) | Immunoconjugates | |
| Burns | The Major Clinical Components of Cancer Immunotherapy (Modulating Cell-Mediated Immune Mechanisms) | |
| Bridgeman et al. | T-Bodies: Antibody-Based Engineered T-Cell Receptors | |
| HK40074322B (en) | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same |